Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this systematic review, animal studies showed that cytarabine causes multi-organ toxicities, notably neurotoxicity, linked to oxidative stress and other mechanisms, though study quality raises concerns about reliability and translation to human outcomes.

This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.

This study found that compound 3 derived from aza-bicyclo-carboxylic acid may exert a cardioprotective effect by reducing infarction area in myocardial ischemia-reperfusion injury, potentially involving A1-adenosine receptor activation and changes in cAMP levels.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

This study found that deleting the ATR gene in adult mice led to rapid onset of age-related traits such as hair graying and osteoporosis through reduced regenerative capacity.

This pilot study found that azelaic acid treatment for patchy alopecia areata had similar hair regrowth results as anthralin, suggesting it may be an effective topical therapy.

This study developed and validated a sensitive liquid chromatography–mass spectrometry method to measure aristolochic acid‐I in rat plasma, successfully applying it to pharmacokinetic research.

In this study, researchers investigated the effects of Aqueous Artocarpus heterophyllus seed extract on testosterone enanthate-induced benign prostatic hyperplasia in adult Wistar rats, using three different dosages to assess its potential as an alternative therapy. Results are not reported in this abstract.

This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.

This study elucidated the multi-component and multi-target mechanisms by which TR and Am may provide therapeutic benefits for treating androgenetic alopecia.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

This study found that certain pyrazole derivatives may serve as effective 5α-reductase inhibitors with potential use in the treatment of androgenetic alopecia, based on molecular docking analyses.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

This review discusses azelaic acid's mechanisms and uses in dermatology, noting its effectiveness in treating conditions like rosacea, acne, and melasma, but reports no new clinical results.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study suggests that the neurosteroid allopregnanolone contributes to stress resistance in mice, and the ALLO mimetic drug alfaxalone may offer anxiolytic benefits without muscle-relaxant effects.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This study identified neprilysin as a potential target of the pharmacological agent arteannuin, which may guide future research into its clinical applications, although experimental verification is needed.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This review provides an overview of azelaic acid's dermatological uses, mechanisms, and its potential in skin cancer treatment, but reports no new clinical results.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

This study found that A(3)B(5) downregulates melanin production and suppresses melanoma cell growth by promoting proteasomal degradation of TRP-2.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.